Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer
A pretreatment model for who will benefit from checkpoint inhibition, built on clinical and molecular covariates rather than on treatment response.
The Lancet Digital Health, 2023.
Note
Uses pretreatment clinical and molecular data to estimate who will benefit from checkpoint inhibition in a cohort of patients with non-small-cell lung cancer, with the aim of producing an estimate before the first cycle rather than after it.
Reference
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer The Lancet Digital Health, 2023. https://scholar.google.com/scholar?q=%22Predicting%20benefit%20from%20immune%20checkpoint%20inhibitors%20in%20patients%20with%20non-small-cell%20lung%20cancer%22
The publisher record holds the author list.
Details
- TypeJournal article
- AreasCancer data science and precision oncology, Medical imaging and computer vision
More from the index
- PreviousA Deep Learning-Based Sensor Modeling for Smart Irrigation SystemAgronomy
- NextMachine Learning Models for the Identification of Prognostic and Predictive Cancer BiomarkersInternational Journal of Molecular Sciences